MGTA-456 in Patients With Inherited Metabolic Disorders Undergoing Hematopoietic Stem Cell Transplantation (HSCT)
Status:
Completed
Trial end date:
2021-01-15
Target enrollment:
Participant gender:
Summary
This study is designed to assess the safety and efficacy of using MGTA-456 in patients with
Inherited Metabolic Disorders (IMD) undergoing stem cell transplantation.